Seelos Therapeutics, Inc. Overview
Pro stress-test →Seelos Therapeutics is a clinical-stage biopharmaceutical company focused on the development and commercialization of therapeutics for the treatment of central nervous system and other disorders. The company's lead programs include intranasal ketamine for acute suicidal ideation, CRISPR gene therapy for Parkinson's disease, and protein stabilizer for ALS and other neurodegenerative conditions.
Strategic Profile
Pro stress-test →The company received notice of delisting from Nasdaq in October 2024 due to non-compliance with the minimum stockholder's equity requirement and began trading on the OTCQB. Despite regulatory headwinds, Seelos received grant funding from the Michael J. Fox Foundation to advance its lead gene therapy candidate SLS-004 for Parkinson's disease, signaling external validation of its pipeline.
Competitive Landscape
Pro stress-test →Seelos operates in the clinical-stage psychedelic and gene therapy space for CNS disorders. Competitors include traditional pharmaceutical companies with established PTSD/depression programs (e.g., Sage Therapeutics, Perception Neuroscience), and gene therapy platforms in Parkinson's (e.g., Spark Therapeutics, REGENXBIO). Seelos's small scale and financial distress place it at a significant competitive disadvantage versus well-capitalized rivals.
Industry Context
Seelos Therapeutics, Inc. operates in Clinical-stage biopharmaceutical development (CNS therapeutics).
Key facts
Founded: 2016 · Headquarters: New York, US · Employees: 8 · Revenue: Minimal/Not publicly disclosed · Market cap: $0.1M